Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model.
Costa WC, Beltrami VA, Campolina-Silva GH, Queiroz-Junior CM, Florentino RM, Machado JR, Martins DG, Gonçalves WA, Barroso LC, Freitas KM, de Souza-Neto FP, Félix FB, da Silva RF, Oliveira CA, Câmara NOS, Rachid MA, Teixeira MM, Rezende BM, Pinho V.
Costa WC, et al. Among authors: pinho v.
Int Immunopharmacol. 2023 Feb;115:109583. doi: 10.1016/j.intimp.2022.109583. Epub 2023 Jan 5.
Int Immunopharmacol. 2023.
PMID: 36610330
Free article.